Growth Metrics

Solid Biosciences (SLDB) Share-based Compensation (2017 - 2026)

Quarterly results put Share-based Compensation at $5.2 million for Q1 2026, up 54.21% from a year ago — trailing twelve months through Mar 2026 was $18.7 million (up 52.87% YoY), and the annual figure for FY2025 was $16.9 million, up 60.79%.

Solid Biosciences has reported Share-based Compensation over the past 10 years, most recently at $5.2 million for Q1 2026.

  • Share-based Compensation reached $5.2 million in Q1 2026 per SLDB's latest filing, down from $6.5 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $6.5 million in Q4 2025 and bottomed at $1.5 million in Q3 2022.
  • Median Share-based Compensation over the past 5 years was $2.1 million (2023), compared with a mean of $2.8 million.
  • The largest annual shift saw Share-based Compensation plummeted 55.39% in 2022 before it skyrocketed 107.39% in 2025.
  • Over 5 years, Share-based Compensation stood at $1.6 million in 2022, then increased by 22.12% to $1.9 million in 2023, then skyrocketed by 97.16% to $3.8 million in 2024, then skyrocketed by 70.11% to $6.5 million in 2025, then dropped by 20.74% to $5.2 million in 2026.
  • Business Quant data shows Share-based Compensation for SLDB at $5.2 million in Q1 2026, $6.5 million in Q4 2025, and $3.9 million in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Share-based Compensation (Qtr)
1 Quantum Biopharma 1,384,976.65 Bn 1,384,976.64 Bn - 892,057.00
2 Alterity Therapeutics 777,208.84 Bn 777,208.81 Bn - -
3 Legend Biotech 2,801.00 Bn 2,800.10 Bn 242.10 Mn -
4 Nanobiotix 2,226.01 Bn 2,225.95 Bn - -
5 Akari Therapeutics 605.66 Bn 605.66 Bn - 305,000.00
6 Vertex Pharmaceuticals 110.17 Bn 102.92 Bn 2.59 Bn 166.40 Mn
7 Regeneron Pharmaceuticals 66.86 Bn 58.11 Bn 3.31 Bn 257.40 Mn
8 Evaxion A 65.12 Bn 65.10 Bn - -
9 Alnylam Pharmaceuticals 39.94 Bn 36.94 Bn 959.66 Mn 70.15 Mn
10 Solid Biosciences 713.77 Mn 333.09 Mn - 5.15 Mn

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 5.15 Mn
Mar 31, 2026 5.15 Mn
Dec 31, 2025 6.50 Mn
Dec 31, 2025 6.50 Mn
Sep 30, 2025 3.93 Mn
Sep 30, 2025 3.93 Mn
Jun 30, 2025 3.15 Mn
Jun 30, 2025 3.15 Mn
Mar 31, 2025 3.34 Mn
Mar 31, 2025 3.34 Mn
Dec 31, 2024 3.82 Mn
Dec 31, 2024 3.82 Mn
Sep 30, 2024 3.00 Mn
Sep 30, 2024 3.00 Mn
Jun 30, 2024 2.09 Mn
Jun 30, 2024 2.09 Mn
Mar 31, 2024 1.61 Mn
Mar 31, 2024 1.61 Mn
Dec 31, 2023 1.94 Mn
Dec 31, 2023 1.94 Mn
Sep 30, 2023 1.63 Mn
Sep 30, 2023 1.63 Mn
Jun 30, 2023 1.94 Mn
Jun 30, 2023 1.94 Mn
Mar 31, 2023 2.12 Mn
Mar 31, 2023 2.12 Mn
Dec 31, 2022 1.59 Mn
Dec 31, 2022 1.59 Mn
Sep 30, 2022 1.52 Mn
Sep 30, 2022 1.52 Mn
Jun 30, 2022 1.81 Mn
Jun 30, 2022 1.81 Mn
Mar 31, 2022 2.61 Mn
Mar 31, 2022 2.61 Mn
Dec 31, 2021 3.42 Mn
Dec 31, 2021 3.42 Mn
Sep 30, 2021 3.42 Mn
Sep 30, 2021 3.42 Mn
Jun 30, 2021 3.64 Mn
Jun 30, 2021 3.64 Mn
Mar 31, 2021 2.91 Mn
Mar 31, 2021 2.91 Mn
Dec 31, 2020 2.52 Mn
Dec 31, 2020 2.52 Mn
Sep 30, 2020 2.76 Mn
Sep 30, 2020 2.76 Mn
Jun 30, 2020 3.24 Mn
Jun 30, 2020 3.24 Mn
Mar 31, 2020 3.10 Mn
Mar 31, 2020 3.10 Mn
Dec 31, 2019 3.40 Mn
Dec 31, 2019 3.40 Mn
Sep 30, 2019 3.39 Mn
Sep 30, 2019 3.39 Mn
Jun 30, 2019 3.91 Mn
Jun 30, 2019 3.91 Mn
Mar 31, 2019 3.50 Mn
Mar 31, 2019 3.50 Mn
Dec 31, 2018 2.03 Mn
Dec 31, 2018 2.03 Mn
Sep 30, 2018 1.80 Mn
Sep 30, 2018 1.80 Mn
Jun 30, 2018 1.31 Mn
Jun 30, 2018 1.31 Mn
Mar 31, 2018 819,000.00
Mar 31, 2018 819,000.00
Dec 31, 2017 823,000.00
Dec 31, 2017 823,000.00
Sep 30, 2017 790,000.00
Sep 30, 2017 790,000.00
Jun 30, 2017 487,000.00
Jun 30, 2017 487,000.00
Mar 31, 2017 3.23 Mn
Mar 31, 2017 3.23 Mn